Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.60 |
| ▸ | AHCY | P23526 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13975625 | 1.00 | ADORA3 (0.60) | ADORA3SLC29A1AHCYTP53TDP1 | |
| SCHEMBL13966418 | 1.00 | ADORA3 (0.60) | ADORA3SLC29A1AHCYTP53TDP1 | |
| SCHEMBL21139428 | 1.00 | ADORA3 (0.60) | ADORA3SLC29A1AHCYTP53TDP1 | |
| SCHEMBL17371112 | 0.87 | SLC29A1 (0.78) | ADORA3SLC29A1TP53TDP1ADORA1 | |
| SCHEMBL21139431 | 0.87 | SLC29A1 (0.78) | ADORA3SLC29A1TP53TDP1ADORA1 | |
| SCHEMBL17825909 | 0.87 | SLC29A1 (0.78) | ADORA3SLC29A1TP53TDP1ADORA1 | |
| SCHEMBL640072 | 0.87 | SLC29A1 (0.78) | ADORA3SLC29A1TP53TDP1ADORA1 | |
| SCHEMBL640071 | 0.87 | SLC29A1 (0.78) | ADORA3SLC29A1TP53TDP1ADORA1 | |
| SCHEMBL13975623 | 0.87 | SLC29A1 (0.78) | ADORA3SLC29A1TP53TDP1ADORA1 | |
| SCHEMBL13966422 | 0.87 | SLC29A1 (0.78) | ADORA3SLC29A1TP53TDP1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2498774-B1 | DUAL-ACTION COMPOUNDS TARGETING ADENOSINE A2A RECEPTOR AND ADENOSINE TRANSPORTER FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | ACADEMIA SINICA (TW) | 2017-10-11 | — | — | EP | disclosed |
| US-20150374737-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ACADEMIA SINICA (TW) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374737-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885SLC29A1 6/4885AHCY 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.